论文部分内容阅读
乙型肝炎的发病原理和病程与患者的免疫(功能)状态有密切关系。顺利恢复健康者,特异性体液与细胞免疫一般都正常,转为慢性者则免疫功能低下,尤其是细胞免疫,不论用非特异性的淋巴细胞转化试验,还是特异性的白细胞移动抑制试验(下称MIF)或白细胞粘附抑制试验(下称LAI)都支持此说。因此,在目前尚无肝炎特效药物的情况下,设法提高患者的免疫功能似为合理可行之方案。免疫RNA(下称iRNA)带有免疫
Hepatitis B pathogenesis and duration of the patient’s immune (functional) status is closely related. Smooth recovery of health, specific humoral and cellular immunity are generally normal, to those who switch to chronic immunocompromised, especially cellular immunity, whether with non-specific lymphocyte transformation test, or specific leukocyte migration inhibition test (hereinafter referred to as MIF) or leukocyte adhesion inhibition test (hereinafter referred to as LAI) support this. Therefore, in the absence of hepatitis specific drugs at present, try to improve the immune function of patients seems to be a reasonable and feasible solution. Immune RNA (hereinafter referred to as iRNA) with immunity